Close Menu

NEW YORK (GenomeWeb) – Having refined its platform and manufacturing process, diagnostics firm HealthTell has now moved into clinical feasibility studies with the aim of launching its first test by the end of next year, CEO Bill Colston told ProteoMonitor this week.

Launched in 2010 as a spinout from Arizona State University's Biodesign Institute, San Ramon, Calif.-based HealthTell aims to commercialize diagnostics based on the immunosignaturing technology developed by Biodesign researchers, and company co-founders Stephen Johnston, Neal Woodbury, and John Rajasekaran.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.